The Safety and Tolerability of Pirfenidone for BOS After HCT
Status:
Active, not recruiting
Trial end date:
2022-04-27
Target enrollment:
Participant gender:
Summary
This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to
determine the tolerability and safety of pirfenidone in patients with BOS associated with
lung GVHD after hematopoietic cell transplant.